GlassScriptPhysician profile
Margi Shah
NPI 1184762056
$6,033.57
in general payments reported to CMS, 2019-2025
23 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $257 · 2021: $615 · 2022: $720 · 2023: $1,124 · 2024: $1,109 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,832.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.73 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $858.60 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $840.67 | 2021-2025 | Caplyta |
| Alkermes, INC. | $443.65 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $401.21 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $381.15 | 2024-2025 | Fanapt |
| Lundbeck LLC | $345.69 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $292.51 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $281.02 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Allergan, INC. | $272.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.83 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $108.99 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $62.47 | 2024-2025 | Austedo Xr, Uzedy |
| Shire North American Group INC | $55.78 | 2019 | |
| Almatica Pharma LLC | $45.28 | 2025 | Loreev Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $41.88 | 2024 | |
| Avanir Pharmaceuticals, INC. | $32.04 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.34 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.97 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.93 | 2022 | |
| Neuronetics, INC. | $14.88 | 2025 | Neurostar Tms Therapy System |
| Eisai INC. | $14.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.45 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margi Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.